Skip to main content
Caplight Logo









AviadoBio

AviadoBio

Private
LondonHealthcare & Life Scienceshttps://aviadobio.com

Last Round

Grant

Mar 31, 2026

Est. Valuation

$320M

Total Funding Raised

$118.89M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

AviadoBio operates in Healthcare & Life Sciences and is based in London. Its latest recorded funding round was a Grant round in March 2026.

AviadoBio is a biotechnology company that develops innovative gene therapies aimed at transforming the lives of individuals affected by severe neurodegenerative diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Pricing history

Caplight clients see full MarketPrice™ history and secondary transactions.

Book a demo

For institutional investors. Book with your work email.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

Momentum history

Caplight clients track how buyer interest and sentiment change over time.

Book a demo

For institutional investors. Book with your work email.

AviadoBio Comparables

Compare AviadoBio with similar companies based on industry and business-model similarity.

AviadoBio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Coave Therapeutics
84%
Capsida Biotherapeutics
81%
DegenRx B.V.
79%
Book a demo to see all comparables

For institutional investors. Book with your work email.

AviadoBio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantMar 31, 2026
StrategicOct 8, 2024
Series ADec 2, 2021
SeedApr 1, 2021
Book a demo to see all funding rounds

For institutional investors. Book with your work email.

Key People

Founding team and executive leadership

Lisa Deschamps

Chief Executive Officer Board Member

Executive Team

Graeme Fielder

Chief Operating Officer

Executive Team

For institutional investors. Book with your work email.

AviadoBio Investors

Notable investors and investment history

Book a demo to see all 13 investors

For institutional investors. Book with your work email.

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 27, 2026

    Combining RNAi platform with TfR1 capsid for CNS gene silencing.

  • Apr 27, 2026

    Presenting drug candidate data at the ASGCT Annual Meeting.

Book a demo to see all signals

For institutional investors. Book with your work email.

Recent news

Latest coverage and updates

  • attends_eventOct 29, 2026

    AviadoBio Ltd presents new preclinical data on the vMiX(TM) platform for AVB-406 and AVB-SNCA at ESGCT 2026.

  • attends_eventOct 8, 2026

    AviadoBio Ltd plans to present preliminary data from the ongoing Phase 1/2 ASPIRE-FTD trial, including early dose-dependent increases in cerebrospinal fluid progranulin across four ascending doses, at the 15th International Conference on Frontotemporal Dementias.

Book a demo to see all news

For institutional investors. Book with your work email.

AviadoBio Filings

Explore SEC and related filing metadata, where available.

AviadoBio filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Book a demo

For institutional investors. Book with your work email.

Frequently Asked Questions

Common questions about AviadoBio's valuation, stock price, and market status.

Is AviadoBio a public or private company?

AviadoBio is a private company.

What is the current stock price of AviadoBio?

AviadoBio is a private company, so its shares have no public market price. Caplight tracks AviadoBio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is AviadoBio worth (valuation)?

AviadoBio's valuation is estimated at $320.0M based on funding round data.

Can I buy AviadoBio stock?

AviadoBio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was AviadoBio's last funding round?

AviadoBio's most recent funding round was Grant on March 31, 2026.

Who are the main investors in AviadoBio?

Key investors in AviadoBio include New Enterprise Associates, Monograph Capital, Johnson & Johnson Innovation – JJDC.

Will AviadoBio IPO soon?

No public IPO plans have been announced for AviadoBio.

How can I track AviadoBio secondary market activity?

Caplight tracks bids, offers, and trades in AviadoBio's shares on secondary markets.

Firmographic Details

HeadquartersLondon
Employee Range49
Year Founded2019
Last FundingMar 31, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Book a demo

For institutional investors. Book with your work email.

See something wrong or outdated?